- Company raised $250 million in IPO, private placement
- Existing investor AyurMaya bought 2.5 million shares
Shares of Alumis Inc. sank 20% in the clinical stage biopharmaceutical company’s public debut, after it raised $250 million in a downsized initial public offering with a concurrent private placement.
The company’s shares declined on Friday to $12.70 each as of 1:00 p.m. in New York. It sold about 13.1 million shares Thursday, as well as 2.5 million shares in a concurrent private placement to one of its investors, at $16 each.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.